<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600742</url>
  </required_header>
  <id_info>
    <org_study_id>201110052MB</org_study_id>
    <nct_id>NCT01600742</nct_id>
  </id_info>
  <brief_title>Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis</brief_title>
  <official_title>Vorinostat and Concomitant Whole Brain Radiation Therapy in Patients With Brain Metastases: A Randomized, Double-blind, Placebo-controlled, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vorinostat is a potent and well tolerated HDAC inhibitor. It has been reported to enhance&#xD;
      radiosensitivity of cancer cells. We hypothesize that the addition of vorinostat to WBRT may&#xD;
      increase therapeutic efficacy for patients with brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Whole brain radiotherapy (WBRT) is the treatment of choice for the majority of patients with&#xD;
      brain metastases. Although WBRT yields high radiologic response rate (27~56%) and is&#xD;
      effective in palliation of neurologic symptoms, the response duration is limited and&#xD;
      neurologic progression remains the main cause of death in a significant number of patients.&#xD;
&#xD;
      Vorinostat is reasonably well tolerated and there is also compelling evidence that vorinostat&#xD;
      may serve as a radiosensitizer. Preclinical studies of HDAC inhibition have also shown&#xD;
      efficacy in neuron protection. These data suggest that the addition of vorinostat to the&#xD;
      standard therapy of WBRT may potentially increase their therapeutic efficacy without&#xD;
      increasing neurotoxicity, and support the rationale of this phase II trial of vorinostat with&#xD;
      WBRT in patients with brain metastases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor stops to provide the study drug.&#xD;
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate brain-specific progression free survival rate at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>brain-specific PFS</measure>
    <time_frame>from randomization to progression of brain metastasis or death, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from randomization to progression or death, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to neuro-cognitive progression</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to neurologic progression</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQoL</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from randomization to death, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Brain Metastasis</condition>
  <arm_group>
    <arm_group_label>WBRT, placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WBRT and concurrent vorinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Run-in phase:&#xD;
WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.&#xD;
Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.&#xD;
Randomization phase:&#xD;
WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.&#xD;
Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT.</description>
    <arm_group_label>WBRT and concurrent vorinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomization phase:&#xD;
WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.&#xD;
Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT.</description>
    <arm_group_label>WBRT, placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a histologic diagnosis of a malignancy (lung and breast cancers) and&#xD;
             radiologic evidence of brain metastases that are not suitable for surgery or&#xD;
             radiosurgery as judged on the basis of the lesion size, number, location and the&#xD;
             patients' personal choices.&#xD;
&#xD;
          -  Patients with controlled systemic disease for &gt;6 weeks (as judged on a case by case&#xD;
             situation)&#xD;
&#xD;
          -  Age≧20 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≦3&#xD;
&#xD;
          -  Life expectancy of ≧6 months&#xD;
&#xD;
          -  No prior cranial radiotherapy&#xD;
&#xD;
          -  Negative urine pregnancy test done ≤7 days prior to registration, for women of&#xD;
             childbearing potential only.&#xD;
&#xD;
          -  Measurable lesions by gadolinium-enhanced MRI or contrast-enhanced CT scans. (≧10mm on&#xD;
             T1-weighted gadolinium enhanced MRI or contrast-enhanced CT)&#xD;
&#xD;
          -  Patients must have adequate organ and marrow reserve measured within 7 days prior to&#xD;
             randomization as defined below:&#xD;
&#xD;
               1. Hemoglobin &gt;8.0 gm/dL;&#xD;
&#xD;
               2. Absolute neutrophil count &gt; 1,000/mcL;&#xD;
&#xD;
               3. Platelets &gt;100,000/mcL;&#xD;
&#xD;
               4. Total bilirubin ≤ 1.5 x UNL (upper normal limit);&#xD;
&#xD;
               5. AST(SGOT)/ALT(SGPT) ≤ 2.5 x UNL; for patients with liver metastases,&#xD;
                  AST(SGOT)/ALT(SGPT) ≤ 5 x UNL is allowed;&#xD;
&#xD;
               6. Serum creatinine ≤ 1.5 x UNL;&#xD;
&#xD;
               7. PTT ≤ UNL;&#xD;
&#xD;
               8. INR ≤ 1.5;&#xD;
&#xD;
               9. Serum sodium, calcium, potassium, and magnesium levels are within normal limits.&#xD;
&#xD;
          -  Patients (or a surrogate) must be able to comply with study procedures and sign&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior cranial RT.&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of vorinostat.&#xD;
&#xD;
          -  Use of Valproic acid or other histone deacetylase inhibitor, ≤2 weeks prior to&#xD;
             registration and during treatment.&#xD;
&#xD;
          -  Uncontrolled infection.&#xD;
&#xD;
          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study or&#xD;
             interfere significantly with the proper assessment of safety and adverse events of the&#xD;
             prescribed regimens or limit compliance with study requirements.&#xD;
&#xD;
          -  History of myocardial infarction or unstable angina ≤6 months prior to registration or&#xD;
             congestive heart failure (CHF) requiring use of ongoing maintenance therapy, or&#xD;
             life-threatening ventricular arrhythmias.&#xD;
&#xD;
          -  Inability to take oral medications.&#xD;
&#xD;
          -  Receiving any other investigational agent.&#xD;
&#xD;
          -  Congenital long QT syndrome.&#xD;
&#xD;
          -  Prolonged QTc interval (&gt;450 msec)&#xD;
&#xD;
          -  Any of the following Category I drugs that are generally known to have a risk of&#xD;
             causing Torsades de Pointes ≤7 days prior to registration: Quinidine, procainamide,&#xD;
             disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycin,&#xD;
             clarithromycin, chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide,&#xD;
             cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone,&#xD;
             halofantrine, levomethadyl, pentamidine&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               1. Pregnant women&#xD;
&#xD;
               2. Nursing women&#xD;
&#xD;
               3. Men or women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception throughout the duration of the study and for 3 weeks after&#xD;
                  treatment has ended.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei-Fang Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

